A Phase II Single Arm Clinical Trial of Nivolumab (BMS-936558) in Subjects with Metastatic or Unresectable Urothelial Cancer who Have Progressed or Recurred Following Treatment with a Platinum Agent - Stand Up To Cancer

Blog

Posted October 14, 2019

A Phase II Single Arm Clinical Trial of Nivolumab (BMS-936558) in Subjects with Metastatic or Unresectable Urothelial Cancer who Have Progressed or Recurred Following Treatment with a Platinum Agent

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.